Skip to Content

Nymox Pharmaceutical Corp NYMX

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

Nymox Pharmaceutical Corp is a biopharmaceutical company. The firm and its subsidiaries specialize in the research and development of drugs and diagnostic products for the aging population. Its product portfolio consists of Nic alert and Tobac alert. The firm has Research and development of products for the aging population reportable segment. It operates mainly in Canada, the United States and Europe and other countries. The company generates a majority of its sales from the United States.

Contact
Bay & Deveaux Streets
Nassau, Bahamas
T +1 800 936-9669
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Jun 30, 2021
Fiscal Year End Dec 31, 2020
Stock Type
Employees 3